Abstract
Twenty-seven cases were treated with BB-K8, a new derivative of kanamycin acylated with l-(-)-gamma-amino-alpha-hydroxybutyric acid at the C-1 amino group of the 2-deoxystreptamine moiety. The majority of them were acute primary pyoderma and acute secondary pyoderma. BB-K8 was effective in 23 cases (85.2%) out of 27 cases treated and no side effect was encountered. BB-K8 had antibacterial activity against not only Staphylococcus but also Pseudomonas and Klebsiella. Thus, BB-K8 was considered to be effective in acute pyodermic condition.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.